This study is in progress, not accepting new patients
First-in-Human Study of TAK-280 in Participants With Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedstudy ends around
- Principal Investigator
- by Bridget Keenan
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Bridget Keenan
Dr. Keenan completed her MD and PhD at the Johns Hopkins University School of Medicine, where she focused on using cancer vaccines to overcome immune suppression in the tumor microenvironment in mouse models of pancreatic cancer. She completed her Internal Medicine residency and Hematology/Oncology fellowship at UCSF.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Takeda
- ID
- NCT05220098
- Phase
- Phase 1/2 Solid Tumor Research Study
- Study Type
- Interventional
- Participants
- About 69 people participating
- Last Updated